FDA Plans Quick Review of Psychedelic Drugs as Mental Health Treatments

Regulators did not identify the companies receiving vouchers.

The U.S. Food and Drug Administration in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

The Food and Drug Administration on April 24 said it will seek fast trials for three psychedelic drugs, including psilocybin, one week after President Donald Trump’s directive to accelerate access to psychedelic treatments for mental health conditions.

Three national priority vouchers are being issued, including two for psilocybin, the FDA said in a statement.